Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axonics, Inc. stock logo
AXNX
Axonics
$70.98
+0.8%
$70.61
$66.32
$71.05
$3.63B0.82469,887 shs4.23 million shs
Medtronic plc stock logo
MDT
Medtronic
$88.48
-1.5%
$91.02
$75.96
$96.25
$113.48B0.86.57 million shs7.06 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axonics, Inc. stock logo
AXNX
Axonics
0.00%0.00%0.00%0.00%+2.91%
Medtronic plc stock logo
MDT
Medtronic
+2.63%-0.27%-2.26%+12.57%+3.18%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Axonics, Inc. stock logo
AXNX
Axonics
N/AN/AN/AN/AN/AN/AN/AN/A
Medtronic plc stock logo
MDT
Medtronic
4.3533 of 5 stars
2.24.03.34.02.92.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axonics, Inc. stock logo
AXNX
Axonics
2.00
HoldN/AN/A
Medtronic plc stock logo
MDT
Medtronic
2.44
Hold$96.078.57% Upside

Current Analyst Ratings Breakdown

Latest AXNX and MDT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/4/2025
Medtronic plc stock logo
MDT
Medtronic
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$92.00 ➝ $107.00
2/19/2025
Medtronic plc stock logo
MDT
Medtronic
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$105.00 ➝ $105.00
2/19/2025
Medtronic plc stock logo
MDT
Medtronic
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$85.00 ➝ $95.00
2/19/2025
Medtronic plc stock logo
MDT
Medtronic
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
2/19/2025
Medtronic plc stock logo
MDT
Medtronic
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$90.00 ➝ $91.00
2/12/2025
Medtronic plc stock logo
MDT
Medtronic
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
(Data available from 4/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axonics, Inc. stock logo
AXNX
Axonics
$366.38M9.90$0.13 per share561.96$12.59 per share5.64
Medtronic plc stock logo
MDT
Medtronic
$33.20B3.42$7.25 per share12.21$38.69 per share2.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axonics, Inc. stock logo
AXNX
Axonics
-$6.09M-$0.12N/A80.66N/A-1.31%0.36%0.31%N/A
Medtronic plc stock logo
MDT
Medtronic
$3.68B$3.2926.8915.182.2212.83%14.07%7.70%5/21/2025 (Estimated)

Latest AXNX and MDT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/18/2025Q3 2025
Medtronic plc stock logo
MDT
Medtronic
$1.36$1.39+$0.03$1.01$8.33 billion$8.29 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Axonics, Inc. stock logo
AXNX
Axonics
N/AN/AN/AN/AN/A
Medtronic plc stock logo
MDT
Medtronic
$2.803.16%+4.14%85.11%48 Years

Latest AXNX and MDT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/6/2025
Medtronic plc stock logo
MDT
Medtronic
quarterly$0.703%3/28/20253/28/20254/11/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axonics, Inc. stock logo
AXNX
Axonics
N/A
8.16
6.40
Medtronic plc stock logo
MDT
Medtronic
0.48
1.90
1.39

Institutional Ownership

CompanyInstitutional Ownership
Axonics, Inc. stock logo
AXNX
Axonics
99.48%
Medtronic plc stock logo
MDT
Medtronic
82.06%

Insider Ownership

CompanyInsider Ownership
Axonics, Inc. stock logo
AXNX
Axonics
1.85%
Medtronic plc stock logo
MDT
Medtronic
0.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Axonics, Inc. stock logo
AXNX
Axonics
61051.11 million50.16 millionOptionable
Medtronic plc stock logo
MDT
Medtronic
95,0001.28 billion1.28 billionOptionable

Recent News About These Companies

2 Value Stocks I'm Buying Right Now
Top Stock Reports for Mastercard, Medtronic & HCA Healthcare
Stifel Nicolaus Sticks to Its Hold Rating for Medtronic (MDT)
TD Cowen Remains a Buy on Medtronic (MDT)
Why Medtronic Stock Marched Higher on Monday
Medtronic plc stock logo
Medtronic (NYSE:MDT) Trading 1.9% Higher - Here's Why

New MarketBeat Followers Over Time

Media Sentiment Over Time

Axonics stock logo

Axonics NASDAQ:AXNX

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Medtronic stock logo

Medtronic NYSE:MDT

$88.48 -1.38 (-1.53%)
Closing price 03:59 PM Eastern
Extended Trading
$88.11 -0.38 (-0.42%)
As of 06:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.